A case of bronchial asthma caused by exposure to aspergillus oryzae in a japanese rice wine brewery worker
Arerugi. 2022;71(4):321-327. doi: 10.15036/arerugi.71.321.ABSTRACTA-55-year-old man who have been working in a Sake (Japanese rice wine) brewer for 27 years, came to the outpatient clinic because cough, dyspnea, and wheeze gradually worsen. These symptoms occurred immediately after exposure to Aspergillus oryzae in the brewing process since age 43. A dust mask was required to reduce these symptoms, but that work was interrupted by exacerbation of these symptoms. These symptoms disappeared when he was away from the on-site work. The SMART therapy using combined inhaler of budesonide (ICS) with formoterol (LABA) was effectiv...
Source: Arerugi - June 12, 2022 Category: Allergy & Immunology Authors: Hiroaki Kume Hikaru Tomita Atsuro Fukuhara Source Type: research
A case of bronchial asthma caused by exposure to aspergillus oryzae in a japanese rice wine brewery worker
Arerugi. 2022;71(4):321-327. doi: 10.15036/arerugi.71.321.ABSTRACTA-55-year-old man who have been working in a Sake (Japanese rice wine) brewer for 27 years, came to the outpatient clinic because cough, dyspnea, and wheeze gradually worsen. These symptoms occurred immediately after exposure to Aspergillus oryzae in the brewing process since age 43. A dust mask was required to reduce these symptoms, but that work was interrupted by exacerbation of these symptoms. These symptoms disappeared when he was away from the on-site work. The SMART therapy using combined inhaler of budesonide (ICS) with formoterol (LABA) was effectiv...
Source: Allergology International - June 12, 2022 Category: Allergy & Immunology Authors: Hiroaki Kume Hikaru Tomita Atsuro Fukuhara Source Type: research
A case of bronchial asthma caused by exposure to aspergillus oryzae in a japanese rice wine brewery worker
Arerugi. 2022;71(4):321-327. doi: 10.15036/arerugi.71.321.ABSTRACTA-55-year-old man who have been working in a Sake (Japanese rice wine) brewer for 27 years, came to the outpatient clinic because cough, dyspnea, and wheeze gradually worsen. These symptoms occurred immediately after exposure to Aspergillus oryzae in the brewing process since age 43. A dust mask was required to reduce these symptoms, but that work was interrupted by exacerbation of these symptoms. These symptoms disappeared when he was away from the on-site work. The SMART therapy using combined inhaler of budesonide (ICS) with formoterol (LABA) was effectiv...
Source: Arerugi - June 12, 2022 Category: Allergy & Immunology Authors: Hiroaki Kume Hikaru Tomita Atsuro Fukuhara Source Type: research
A case of bronchial asthma caused by exposure to aspergillus oryzae in a japanese rice wine brewery worker
Arerugi. 2022;71(4):321-327. doi: 10.15036/arerugi.71.321.ABSTRACTA-55-year-old man who have been working in a Sake (Japanese rice wine) brewer for 27 years, came to the outpatient clinic because cough, dyspnea, and wheeze gradually worsen. These symptoms occurred immediately after exposure to Aspergillus oryzae in the brewing process since age 43. A dust mask was required to reduce these symptoms, but that work was interrupted by exacerbation of these symptoms. These symptoms disappeared when he was away from the on-site work. The SMART therapy using combined inhaler of budesonide (ICS) with formoterol (LABA) was effectiv...
Source: Allergology International - June 12, 2022 Category: Allergy & Immunology Authors: Hiroaki Kume Hikaru Tomita Atsuro Fukuhara Source Type: research
Combination fixed-dose {beta} agonist and steroid inhaler as required for adults or children with mild asthma: a Cochrane systematic review
Conclusions
FABA/ICS as required is clinically effective in adults and adolescents with mild asthma and reduced exacerbations, hospital admissions or unscheduled healthcare visits and exposure to systemic corticosteroids and probably reduces adverse events compared with FABA as required alone. FABA/ICS as required is as effective as regular ICS and reduced asthma-related hospital admissions or unscheduled healthcare visits, and average exposure to ICS, and is unlikely associated with increased adverse events. (Source: Evidence-Based Medicine)
Source: Evidence-Based Medicine - May 24, 2022 Category: Internal Medicine Authors: Crossingham, I., Turner, S., Ramakrishnan, S., Fries, A., Gowell, M., Yasmin, F., Richardson, R., Webb, P., O'Boyle, E., Hinks, T. S. C. Tags: Open access, Primary care Evidence synthesis Source Type: research
Clinical Efficacy of Budesonide/Glycopyrronium Bromide/Formoterol in the Treatment of Patients with Acute Respiratory Distress Syndrome and Its Effect on Inflammatory Factors
CONCLUSION: Adjuvant therapy with Breztri Aerosphere in ARDS can significantly lower APACHE II scores and Murray lung injury scores, improve blood gas indexes and pulmonary circulation function indexes, and shorten mechanical ventilation time and ICU time, which may be attributed to its improvement of organism inflammation status and reduction of inflammatory factors.PMID:35529915 | PMC:PMC9071865 | DOI:10.1155/2022/8150444 (Source: Evidence-based Complementary and Alternative Medicine)
Source: Evidence-based Complementary and Alternative Medicine - May 9, 2022 Category: Complementary Medicine Authors: Haiying Liu Zhengyan Wang Lijun Ren Guiqin Zhang Dan Zhao Yanli Guo Lijuan Wang Hong Feng Source Type: research
A 16-Year-Old-Girl With Asthma, Palpable Purpura, and Hypereosinophilia
Chest. 2022 May;161(5):e305-e308. doi: 10.1016/j.chest.2021.12.632.ABSTRACTA 16-year-old girl presented to the ED with complaints of loose stools, abdominal pain, and rash over her legs for the last 7 days. There was no history of fever, vomiting, oral ulcers, or mucosal bleeds. In the past, she had received a diagnosis of asthma. She had been taking oral montelukast every day for the past year and using a formoterol-budesonide dry powder inhaler irregularly, only during episodes of acute exacerbations. There was a history of significant but undocumented weight loss. On day 3 of hospital admission, she developed numbness o...
Source: Chest - May 8, 2022 Category: Respiratory Medicine Authors: Jasmine Singh Shivani Randev Pankaj Kumar Vidushi Mahajan Phiza Aggarwal Aman Sharma Vishal Guglani Source Type: research
A 16-Year-Old-Girl With Asthma, Palpable Purpura, and Hypereosinophilia
Chest. 2022 May;161(5):e305-e308. doi: 10.1016/j.chest.2021.12.632.ABSTRACTA 16-year-old girl presented to the ED with complaints of loose stools, abdominal pain, and rash over her legs for the last 7 days. There was no history of fever, vomiting, oral ulcers, or mucosal bleeds. In the past, she had received a diagnosis of asthma. She had been taking oral montelukast every day for the past year and using a formoterol-budesonide dry powder inhaler irregularly, only during episodes of acute exacerbations. There was a history of significant but undocumented weight loss. On day 3 of hospital admission, she developed numbness o...
Source: Chest - May 8, 2022 Category: Respiratory Medicine Authors: Jasmine Singh Shivani Randev Pankaj Kumar Vidushi Mahajan Phiza Aggarwal Aman Sharma Vishal Guglani Source Type: research
A 16-Year-Old-Girl With Asthma, Palpable Purpura, and Hypereosinophilia
Chest. 2022 May;161(5):e305-e308. doi: 10.1016/j.chest.2021.12.632.ABSTRACTA 16-year-old girl presented to the ED with complaints of loose stools, abdominal pain, and rash over her legs for the last 7 days. There was no history of fever, vomiting, oral ulcers, or mucosal bleeds. In the past, she had received a diagnosis of asthma. She had been taking oral montelukast every day for the past year and using a formoterol-budesonide dry powder inhaler irregularly, only during episodes of acute exacerbations. There was a history of significant but undocumented weight loss. On day 3 of hospital admission, she developed numbness o...
Source: Chest - May 8, 2022 Category: Respiratory Medicine Authors: Jasmine Singh Shivani Randev Pankaj Kumar Vidushi Mahajan Phiza Aggarwal Aman Sharma Vishal Guglani Source Type: research
Economic Evaluation of Triple Therapy with Budesonide/Glycopyrrolate/Formoterol Fumarate for the Treatment of Moderate to Very Severe Chronic Obstructive Pulmonary Disease in China Using a Semi-Markov Model
ConclusionTriple therapy with BGF was predicted to improve outcomes and be a cost-effective treatment option compared with LAMA/LABA therapies for patients with moderate to very severe COPD in China. (Source: Applied Health Economics and Health Policy)
Source: Applied Health Economics and Health Policy - April 28, 2022 Category: Health Management Source Type: research
Relationship between prior inhaled corticosteroid use and benefits ofbudesonide/glycopyrronium/formoterol fumarate dihydrate on exacerbations, symptoms, health-related quality of life, and lung function in patients with chronic obstructive pulmonary disease: Analyses from the ETHOS study
In the Phase III ETHOS study (NCT02465567), budesonide/glycopyrronium/formoterol fumarate dihydrate (BGF) triple therapy at two inhaled corticosteroid (ICS) doses reduced moderate/severe exacerbation rates and improved symptoms, health-related quality of life (HRQoL), and lung function versus glycopyrronium/formoterol fumarate dihydrate (GFF) or budesonide/formoterol fumarate dihydrate (BFF) dual therapy in patients with moderate-to-very-severe chronic obstructive pulmonary disease (COPD). Here, we assessed whether the benefit for BGF versus GFF was driven by patients who received ICS before randomization to GFF. (Source: ...
Source: Respiratory Medicine - April 22, 2022 Category: Respiratory Medicine Authors: Dave Singh, Klaus F. Rabe, Fernando J. Martinez, Matthias Kr üll, Martin Jenkins, Mehul Patel, Paul Dorinsky Tags: Original Research Source Type: research
Relationship between prior inhaled corticosteroid use and benefits of budesonide/glycopyrronium/formoterol fumarate dihydrate on exacerbations, symptoms, health-related quality of life, and lung function in patients with chronic obstructive pulmonary disease: Analyses from the ETHOS study
In the Phase III ETHOS study (NCT02465567), budesonide/glycopyrronium/formoterol fumarate dihydrate (BGF) triple therapy at two inhaled corticosteroid (ICS) doses reduced moderate/severe exacerbation rates and improved symptoms, health-related quality of life (HRQoL), and lung function versus glycopyrronium/formoterol fumarate dihydrate (GFF) or budesonide/formoterol fumarate dihydrate (BFF) dual therapy in patients with moderate-to-very-severe chronic obstructive pulmonary disease (COPD). Here, we assessed whether the benefit for BGF versus GFF was driven by patients who received ICS before randomization to GFF. (Source: ...
Source: Respiratory Medicine - April 22, 2022 Category: Respiratory Medicine Authors: Dave Singh, Klaus F. Rabe, Fernando J. Martinez, Matthias Kr üll, Martin Jenkins, Mehul Patel, Paul Dorinsky Tags: Original Research Source Type: research
Treatment persistence and exacerbations in patients with asthma initiating treatment with inhaled corticosteroids and beta-adrenergic agonists: retrospective cohort study
Conclusions
Patients undergoing treatment with FP/FORM and FF/VI versus FP/SAL, BDP/FORM and BUD/FORM were associated with greater treatment adherence (persistence, MPR) and lower rates of exacerbations. However, further studies will be needed to strengthen the consistency of the results. (Source: BMJ Open)
Source: BMJ Open - April 20, 2022 Category: General Medicine Authors: Sicras-Mainar, A., Gomez Rodriguez, B., Traseira-Lugilde, S., Fernandez-Sanchez, T., Velasco Garrido, J. L. Tags: Open access, General practice / Family practice Source Type: research
First Symbicort Generic Gains Approval
The FDA recently approved the first generic budesonide and formoterol fumarate dihydrate (Symbicort) to treat asthma and chronic obstructive pulmonary disease (COPD). (Source: JAMA)
Source: JAMA - April 19, 2022 Category: General Medicine Source Type: research
Eosinophil Progenitors in Patients With Non-Asthmatic Eosinophilic Bronchitis, Eosinophilic Asthma, and Normal Controls
ConclusionsNAEB patients have increased airway levels of HPCs and EoPs. One-month treatment with ICS did not fully suppress the level of EoPs in NAEB. Controlling in situ airway differentiation of EoPs may control airway eosinophilia and provide long-term resolution of symptoms in NAEB. (Source: Frontiers in Immunology)
Source: Frontiers in Immunology - March 31, 2022 Category: Allergy & Immunology Source Type: research
